𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion

✍ Scribed by George K. K. Lau

Book ID
111239252
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
184 KB
Volume
30
Category
Article
ISSN
0106-9543

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Comparison of interferon and lamivudine
Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B
✍ Yasuji Arase; Kenji Ikeda; Fumitaka Suzuki; Yoshiyuki Suzuki; Masahiro Kobayashi πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 117 KB πŸ‘ 1 views

## Abstract The aim of this study was to elucidate the long‐term outcome after interferon (IFN) or lamivudine (LMV) treatment in Japanese patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis B. Inclusion criteria were biopsy proven chronic hepatitis or liver cirrhosis, no history

HBeAg and hepatitis B virus DNA as outco
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
✍ Michael W. Fried; Teerha Piratvisuth; George K. K. Lau; Patrick Marcellin; Wan-C πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 414 KB πŸ‘ 2 views

The aims of this study were to evaluate the usefulness of quantitative hepatitis B e antigen (HBeAg) values for predicting HBeAg seroconversion in patients treated with peginterferon alfa-2a and to assess the dynamic changes in quantitative HBeAg during therapy, compared with conventional measures o

Lamivudine maintenance beyond one year a
Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B
✍ Hyun Woong Lee; Heon Ju Lee; Jae Seok Hwang; Joo Hyun Sohn; Jae Young Jang; Ki J πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 283 KB πŸ‘ 1 views

The reported durability of virologic response after successful lamivudine monotherapy is variable, and the question remains as to whether virologic responses can be maintained over an extended follow-up period. The aim of this study was to investigate posttreatment durability, the optimal duration o

A dose-finding study of once-daily oral
A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection
✍ Ching-Lung Lai; Seng Gee Lim; Nathaniel A. Brown; Xiao-Jian Zhou; Deborah M. Llo πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 305 KB πŸ‘ 1 views

Current therapy for chronic hepatitis B is suboptimal as a result of limited durable response rates, cumulative viral resistance, and/or poor tolerability. Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclinical sa